Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Healthtrust
McKinsey
Harvard Business School
Argus Health
Fish and Richardson
Citi
Teva
UBS

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: RE45128

« Back to Dashboard

Which drugs does patent RE45128 protect, and when does it expire?

Patent RE45128 protects SYNRIBO and is included in one NDA.

This patent has twenty-six patent family members in seventeen countries.
Summary for Patent: RE45128
Title:Cephalotaxane derivatives and their processes of preparation and purification
Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: ##STR00001## wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.
Inventor(s): Robin; Jean-Pierre (Geneva, CH), Blanchard; Julie (Puyricard, FR), Marie; Jean-Pierre (Sevres, FR), Radosevic; Nina (Geneva, CH)
Assignee: IVAX International GmbH (Rapperswil, CH)
Application Number:13/661,677
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent RE45128

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF LEUKEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE45128

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France98 03492Mar 20, 1998

Non-Orange Book US Patents Family Members for Patent RE45128

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,774 Cephalotaxane derivatives and their processes of preparation and purification ➤ Sign Up
6,613,900 Cephalotaxane derivatives and process for their preparation ➤ Sign Up
7,842,687 Cephalotaxane derivatives and their processes of preparation and purification ➤ Sign Up
6,831,180 Cephalotaxane derivatives and process for their preparation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Covington
UBS
McKesson
US Army
Farmers Insurance
QuintilesIMS
Julphar
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.